Откази на шенгенски визи в Китай
Откази на шенгенски визи в Китай: Как се представя България и защо е рекордьор по откази?Данните за 2024 г. отново поставят България в тревожно контрастна позиция спрямо водещите държави в…
WithSecure on saattanut päätökseen kyberturvakonsultoinnin liiketoiminnan myynnin Neqstille
WithSecure Corporation, Pörssitiedote, 31.5.2025 klo 9.45 WithSecure on saattanut päätökseen kyberturvakonsultoinnin liiketoiminnan myynnin Neqstille WithSecure tiedotti 23.1.2025 aikeestaan myydä kyberturvakonsultoinnin liiketoiminta ruotsalaiselle sijoitusyhtiö Neqstille. Osapuolet ovat 31.5.2025 saattaneet kaupan päätökseen…
Как ВРЕДИТЕЛСТВОТО съсипва туризма
Години наред Шенген беше цел, кауза, мечта и сега ВРЕДИТЕЛСТВОТО целенасочено съсипва туризма . Политици се снимаха с плакати, обещаваха, убеждаваха ни, че „само това ни липсва“, за да дръпнем…
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37…
Form 8.3 – [GLOBALDATA PLC – 30 05 2025]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Atos Group receives confirmatory offer from the French State to acquire part of its former Advanced Computing business
Press release Atos Group receives confirmatory offer from the French State to acquire part of its former Advanced Computing business Vision AI activities excluded from the transaction Confirmatory offer received…
Le groupe Atos reçoit une offre ferme de l’Etat français pour l’acquisition d’une partie de son ancienne activité de Calcul Avancé
Le groupe Atos reçoit une offre ferme de l'Etat français pour l'acquisition d'une partie de son ancienne activité de Calcul Avancé Les Activités de Vision AI sont exclues de la…
Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1.L’analyse…
Arvinas and Pfizer’s Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable…